Svb Leerink Weighs in on Intersect ENT Inc’s Q1 2020 Earnings (XENT)

Intersect ENT Inc (NASDAQ:XENT) – Equities research analysts at Svb Leerink issued their Q1 2020 earnings per share estimates for shares of Intersect ENT in a report issued on Tuesday, May 7th, according to Zacks Investment Research. Svb Leerink analyst R. Newitter forecasts that the medical equipment provider will post earnings of ($0.08) per share for the quarter. Svb Leerink currently has a “Market Perform” rating and a $29.00 price target on the stock. Svb Leerink also issued estimates for Intersect ENT’s Q2 2020 earnings at ($0.10) EPS, Q3 2020 earnings at ($0.09) EPS and Q4 2020 earnings at ($0.06) EPS.

Several other equities analysts have also weighed in on the stock. Northland Securities lowered shares of Intersect ENT from a “market perform” rating to an “under perform” rating and cut their price objective for the company from $28.00 to $20.00 in a research report on Tuesday, May 7th. Leerink Swann lowered shares of Intersect ENT from an “outperform” rating to a “market perform” rating and set a $25.75 price target on the stock. in a research report on Tuesday, May 7th. BidaskClub raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Tuesday, May 7th. Zacks Investment Research lowered shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a research report on Friday, May 3rd. Finally, BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research report on Tuesday, February 26th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Intersect ENT has an average rating of “Hold” and an average target price of $30.96.

XENT traded down $0.69 during midday trading on Wednesday, hitting $23.58. 458,310 shares of the company’s stock traded hands, compared to its average volume of 378,521. The firm has a market cap of $733.28 million, a PE ratio of -31.03 and a beta of 0.62. Intersect ENT has a one year low of $23.37 and a one year high of $42.95.

Intersect ENT (NASDAQ:XENT) last issued its quarterly earnings data on Monday, May 6th. The medical equipment provider reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.05). The business had revenue of $26.70 million for the quarter, compared to the consensus estimate of $26.34 million. Intersect ENT had a negative net margin of 24.99% and a negative return on equity of 22.90%. Intersect ENT’s revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.21) EPS.

In related news, insider Susan P. Stimson sold 5,350 shares of the business’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $27.38, for a total transaction of $146,483.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Lisa D. Earnhardt sold 9,500 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $25.59, for a total transaction of $243,105.00. The disclosure for this sale can be found here. In the last three months, insiders sold 121,096 shares of company stock worth $3,658,625. Insiders own 5.90% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp increased its holdings in shares of Intersect ENT by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 144,802 shares of the medical equipment provider’s stock worth $4,163,000 after buying an additional 4,756 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Intersect ENT by 12.9% during the 3rd quarter. BlackRock Inc. now owns 2,607,083 shares of the medical equipment provider’s stock worth $74,954,000 after buying an additional 296,973 shares during the last quarter. Man Group plc increased its holdings in shares of Intersect ENT by 32.2% during the 3rd quarter. Man Group plc now owns 10,289 shares of the medical equipment provider’s stock worth $296,000 after buying an additional 2,509 shares during the last quarter. MetLife Investment Advisors LLC increased its holdings in shares of Intersect ENT by 55.2% during the 3rd quarter. MetLife Investment Advisors LLC now owns 21,677 shares of the medical equipment provider’s stock worth $623,000 after buying an additional 7,706 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Intersect ENT by 18.9% during the 3rd quarter. AQR Capital Management LLC now owns 51,917 shares of the medical equipment provider’s stock worth $1,493,000 after purchasing an additional 8,253 shares during the period. 92.00% of the stock is currently owned by institutional investors and hedge funds.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: Momentum Indicators

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.